1. Clinical characteristics, patterns of lipid-lowering medication use, and health care resource utilization and costs among patients with atherosclerotic cardiovascular disease.
- Author
-
Power TP, Ke X, Zhao Z, Bonine NG, Cziraky MJ, Grabner M, Barron JJ, Quimbo R, Vangerow B, and Toth PP
- Subjects
- Aged, Atherosclerosis blood, Atherosclerosis diagnosis, Biomarkers blood, Databases, Factual, Drug Utilization Review, Female, Guideline Adherence economics, Health Resources statistics & numerical data, Health Resources trends, Humans, Hypolipidemic Agents adverse effects, Male, Medication Adherence, Middle Aged, Practice Guidelines as Topic, Practice Patterns, Physicians' trends, Retrospective Studies, Time Factors, Treatment Outcome, United States, Atherosclerosis drug therapy, Atherosclerosis economics, Drug Costs trends, Health Resources economics, Hypolipidemic Agents economics, Hypolipidemic Agents therapeutic use, Lipids blood, Practice Patterns, Physicians' economics
- Abstract
Purpose: The aim of this study was to investigate real-world patient characteristics, medication use, and health care resource utilization (HCRU) and costs among patients with clinical atherosclerotic cardiovascular disease (ASCVD) as defined by 2013 American College of Cardiology/American Heart Association (ACC/AHA) guidelines, to examine burden of disease and unmet needs, such as potential undertreatment., Patients and Methods: This retrospective cohort study utilized a nationally representative managed care database to identify newly diagnosed ASCVD patients between January 1, 2007, and November 30, 2012 (index = first ASCVD diagnosis date) in the USA. Patients had ≥12-month pre-index (baseline) and ≥12-month post-index (follow-up) health plan enrollment and no baseline lipid-lowering medication (LLM). Patient characteristics, LLM utilization patterns, HCRU, and costs were examined for all patients and by subgroups based on LLM use pattern and/or follow-up low-density lipoprotein cholesterol (LDL-C) levels., Results: A total of 128,017 ASCVD patients were identified with a mean (SD) age of 59 (13) years, 43.1% female, and 48.8% with ≥36-month follow-up. Within 12-month follow-up, 10.6% had high-intensity statins and 56.9% had no LLM fills. Baseline mean (SD) all-cause costs were $8,852 ($25,608). At 12-month follow-up, mean (SD) all-cause and ASCVD-related costs were $31,443 ($54,040) and $20,289 ($45,159), respectively. The 36-month analyses showed similar distributions. Multivariable analyses showed that age, gender, region, health insurance type, baseline comorbidities, baseline use of specific medications, baseline lipid profiles, and index ASCVD type were significantly associated with all-cause and ASCVD-related health care costs., Conclusion: Patients have nonoptimal treatment for ASCVD and substantial HCRU and costs associated with residual risk. Unmet needs and cost burdens of ASCVD patients merit additional investigation., Competing Interests: Disclosure Thomas P Power is an employee of AIM Specialty Health, a wholly owned subsidiary of Anthem, Inc. Xuehua Ke, Mark J Cziraky, Michael Grabner, John J Barron, and Ralph Quimbo are employees of HealthCore, Inc., a wholly owned subsidiary of Anthem, Inc., under contract with Eli Lilly and Company for the conduct of this study. Nicole Gidaya Bonine was an employee of HealthCore, Inc., under contract with Eli Lilly and Company for the conduct of this study at the time of the study. Zhenxiang Zhao and Burkhard Vangerow are employees and stock/shareholders of Eli Lilly and Company. Peter P Toth is an employee of CGH Medical Center and an adjunct associate professor at Johns Hopkins University School of Medicine, under contract with HealthCore, Inc.; has relationships for the following: speakers bureau – Amarin Corporation, AstraZeneca Plc, Genzyme Corporation, GlaxoSmithKline Plc, Kowa Pharmaceuticals America, Inc., and Merck & Co., Inc.; consultant – Amgen, AstraZeneca Plc, Atherotech Diagnostics Lab, Kowa Pharmaceuticals America, Inc., Liposcience, Inc., Merck & Co., Inc., and Novartis Pharmaceuticals Corporation. The authors report no other conflicts of interest in this work.
- Published
- 2018
- Full Text
- View/download PDF